Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1

Status

Terminated 2Completed 2Withdrawn 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2

Conditions

Myeloproliferative Disorders 2Blast Crisis 1

Interventions

Cyclophosphamide 98pembrolizumab 87Gemcitabine 81Carboplatin 63fludarabine 62Nivolumab 57Cisplatin 54Paclitaxel 51Radiotherapy 50Docetaxel 50Rituximab 46Dexamethasone 42Lenalidomide 41Ipilimumab 38Azacitidine 35Etoposide 34Cytarabine 34Temozolomide 32Bevacizumab 32Radiation 29venetoclax 28Bortezomib 27Magnetic Resonance Spectroscopy 26Irinotecan 26atezolizumab 25Pemetrexed 25Oxaliplatin 24Capecitabine 24fludarabine phosphate 23Filgrastim 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Terminated × fedratinib × Clear all
NCT05127174 2025-12-04

Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Terminated
12 enrolled
Myeloid

Myeloproliferative Disorders

NCT05524857 2024-04-23

Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)

Columbia University

Phase 1 Terminated
2 enrolled
Myeloid

Blast Crisis, Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡